Centauri Therapeutics closes £ 24 million Series A investment round
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Funding to grow the insurance and digital therapeutics vertical in India
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Key takeaways of Q3FY22 quarter & conference call highlights
It will open new frontier for south-to-south collaboration and innovation transfer
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Subscribe To Our Newsletter & Stay Updated